Meeting
2014 Breast Cancer Symposium
Patient-reported outcomes (PROs) from TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician’s choice (TPC) in patients with pretreated HER2-positive advanced breast cancer.
Authors
Karen Bartley
Genentech, Inc., South San Francisco, CA
Karen Bartley , Hans Wildiers , Sung-Bae Kim , Ian E. Krop , Jennifer Kang , Ron Yu , Abraham C. F. Leung , Caroline Trudeau , Antonio Gonzalez-Martin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Risk Assessment, Prevention, Early Detection, Screening, and Systemic Therapy
Track
Systemic Therapy,Risk Assessment, Prevention, Early Detection, and Screening
Sub Track
HER2+
Clinical Trial Registration Number
NCT01419197
Citation
J Clin Oncol 32, 2014 (suppl 26; abstr 153)
DOI
10.1200/jco.2014.32.26_suppl.153
Abstract #
153
Poster Bd #
D25
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Patient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab + taxane (HT) for HER2-positive advanced breast cancer.
First Author: Carlos H. Barrios
Poster
2014 ASCO Annual Meeting
Relationship between tumor biomarkers (BM) and efficacy in TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician’s choice (TPC) in HER2-positive advanced breast cancer (BC) previously treated with trastuzumab and lapatinib.
First Author: Sung-Bae Kim
Poster
2023 ASCO Annual Meeting
Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT).
First Author: Michel Delforge
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Symptom burden and functioning status in patients with advanced upper gastrointestinal cancers.
First Author: Xin Shelley Wang